The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

Relay Therapeutics, a US-based cancer drug developer backed by internet group SoftBank and internet technology conglomerate Alphabet, went public yesterday in a $400m initial public offering. The company increased the number of shares in the offering from 14.7 million to 20 million and priced the shares at $20.00 each, above the IPO’s $16 to $18…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.